Vitamin D and Omega-3 Trial (VITAL) was a clinical trial designed to investigate the use of daily dietary supplements of vitamin D and fish oil.
5-422: VITAL may refer to: Vitamin D and Omega-3 Trial , a 7 year clinical trial VHDL-VITAL , VHDL Initiative Towards ASIC Libraries VITAL (machine learning software) VITAL (asset management software) , a software suite of digital asset management products by VTLS based on the open source Fedora architecture VITAL (ventilator) , NASA ventilator developed during
10-700: Is different from Wikidata All article disambiguation pages All disambiguation pages Vitamin D and Omega-3 Trial The sponsor of the study was Brigham and Women's Hospital , collaborating with The National Cancer Institute , National Heart, Lung, and Blood Institute , Office of Dietary Supplements , National Institute of Neurological Disorders and Stroke , National Center for Complementary and Integrative Health , Pharmavite LLC , Pronova BioPharma and BASF . The studied aimed to enroll 20,000 participants (women 55 or over, men 50 or over) who were randomized into one of four groups: Participants answered annual questionnaires to determine effects
15-565: The COVID-19 pandemic See also [ edit ] Vital (disambiguation) Topics referred to by the same term [REDACTED] This disambiguation page lists articles associated with the title VITAL . If an internal link led you here, you may wish to change the link to point directly to the intended article. Retrieved from " https://en.wikipedia.org/w/index.php?title=VITAL&oldid=1179441225 " Category : Disambiguation pages Hidden categories: Short description
20-488: The risks of developing cancer , heart disease , stroke , osteoporosis , diabetes , memory loss and depression. The outcome of this study was: "The results of this trial indicate that supplementation with either n–3 fatty acid at a dose of 1 g/day or vitamin D3 at a dose of 2000 IU/day was not effective for primary prevention of CV or cancer events among healthy middle-aged men and women over 5 years of follow-up. There
25-459: Was also no difference in progression/development of CKD among patients with type 2 diabetes. This is one of the largest trials on this topic. The finding of a lower MI risk with n–3 fatty acid is hypothesis generating and deserves further study. The authors also noted some interaction with baseline fish consumption, with greater CV benefit observed among participants who had low fish intake at baseline." This medical treatment –related article
#207792